Search

Classifiers are among the most widely used supervised machine learning algorithms. Many classification models exist, and choosing the right one for a given task is difficult. During model selection and debugging, data scientists need to assess classifiers' performances, evaluate their learning behavior over time, and compare different models. Typically, this analysis is based on single-number performance measures such as accuracy. A more detailed evaluation of classifiers is possible by inspecting class errors. The confusion matrix is an established way for visualizing these class errors, but it was not designed with temporal or comparative analysis in mind. More generally, established performance analysis systems do not allow a combined temporal and comparative analysis of class-level information. To address this issue, we propose ConfusionFlow, an interactive, comparative visualization tool that combines the benefits of class confusion matrices with the visualization of performance characteristics over time. ConfusionFlow is model-agnostic and can be used to compare performances for different model types, model architectures, and/or training and test datasets. We demonstrate the usefulness of ConfusionFlow in a case study on instance selection strategies in active learning. We further assess the scalability of ConfusionFlow and present a use case in the context of neural network pruning., Changes compared to previous version: Reintroduced NN pruning use case; restructured Evaluation section; several additional minor revisions. Submitted as Minor Revision to IEEE TVCG on 2020-07-02

Due to the current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, there is an urgent need for novel therapies and drugs. We conducted a large-scale virtual screening for small molecules that are potential CoV-2 inhibitors. To this end, we utilized "ChemAI", a deep neural network trained on more than 220M data points across 3.6M molecules from three public drug-discovery databases. With ChemAI, we screened and ranked one billion molecules from the ZINC database for favourable effects against CoV-2. We then reduced the result to the 30,000 top-ranked compounds, which are readily accessible and purchasable via the ZINC database. Additionally, we screened the DrugBank using ChemAI to allow for drug repurposing, which would be a fast way towards a therapy. We provide these top-ranked compounds of ZINC and DrugBank as a library for further screening with bioassays at https://github.com/ml-jku/sars-cov-inhibitors-chemai., Additional results added. Various corrections to formulations and typos